News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Aug 17, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, 2020, at 10:00 a.m. ET
Corporate Highlights Rajiv Khosla, Ph.D. appointed as Chief Executive Officer of Enteris BioPharma Repurchased $1.0 million of common stock during the three-month span ended June 30, 2020 SWK...
- Aug 14, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, at 10:00 a.m. ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced that the Company will host a conference call and live audio webcast on Monday, August 17, 2020,...
- Jun 29, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today its addition to the broad-market Russell 3000® Index, the Russell 2000® Index and the...
- Jun 23, 2020Presentation Scheduled for June 25, 2020, at 11:30 a.m., ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today that Chairman and CEO Winston Black will present via webcast at the Life Sciences...
- Jun 09, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jun 02, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- May 14, 2020Conference Call and Live Audio Webcast Scheduled for Friday, May 15, 2020, at 10:00 a.m. ET
Corporate Highlights Core specialty finance segment generated an 11.3% adjusted ROIC, and yielding assets increased to $179.2 million, a 15.7% increase in comparison to the quarter ended March 31,...
- May 04, 2020Accomplished Industry Executive Brings Extensive Business Development Experience and Deep Knowledge of Drug Delivery Technology to Enteris
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 30, 2020Transformative 2019 Underscored by Strong Finance Results and Enteris BioPharma Acquisition
Corporate Highlights Core specialty finance segment generated a 12.6% adjusted ROIC and yielding assets increased 4.8% year over year to $175.1 million Closed Enteris Biopharma acquisition SWK...
- Mar 26, 2020SWK Holdings Expects to Report Adjusted Earnings for Fourth Quarter and Year End 2019 of $4.3 to $4.7 million and $21.0 to $21.4 million, respectively
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today announced its preliminary revenue and...
- Feb 28, 2020Specialty Finance Portfolio Performance Highlights Strong Year, Underscored by Enteris BioPharma Acquisition and NASDAQ Uplisting
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and...
- Feb 10, 2020Accomplished Biopharmaceutical and Drug Development Executive to Lead the Expansion of Enteris' External and Internal Development Programs
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 27, 2020Enteris recognized for enhancing positive image of small businesses and service to customers
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 23, 2020Trading begins today, January 23, 2020, under the ticker symbol "SWKH"
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its shares of common stock will begin trading on the Nasdaq Capital Market beginning...
- Jan 21, 2020Trading to begin on January 23, 2020
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, today announced that its shares of common stock have been approved for listing on the...
- Jan 06, 2020A transformational 2019 positions Enteris to capitalize on potential of Peptelligence®
Acquired by SWK Holdings Corporation; Now Operating as a Wholly Owned Subsidiary Focused on Advancement of Peptelligence-Driven External Partnerships and Internal Drug Development Pipeline Entered...
- Dec 09, 2019New Hygiene Laser designed by Dental Hygienists for Dental Hygienists
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced the launch of their new Epic Hygiene laser at the Greater New York Dental Meeting, in New York City from Nov. 29 - Dec....
- Dec 06, 2019Oral KORSUVA 1 mg met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores vs. placebo after 12-week treatment period (p=0.018)
Boonton, NJ – December 6, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned...
- Dec 05, 2019
MIAMI, Dec. 05, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of...
- Dec 04, 2019
Lake Forest, Calif. – December 4, 2019 – Tenex Health, Inc., a privately held, U.S.-based medical technology company providing healthcare professionals with minimally invasive technologies to...
- Dec 02, 2019~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~
DEER PARK, Ill., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 26, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to present at the following two investor conferences in December: 8th Annual Benchmark...
- Nov 21, 2019Board Realignment Follows SWK's Acquisition of Enteris BioPharma
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced today that Winston Black, Chief Executive Officer of SWK, has been named...
- Nov 18, 2019
Corporate Highlights Acquired Enteris BioPharma, Inc. ("Enteris") a biotechnology company offering innovative formulation solutions utilizing its proprietary oral drug delivery technology,...
- Nov 15, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 15, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Nov 15, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it appointed Michael DiTolla, DDS, FAGD to its board of directors, effective November 14, 2019. The appointment...
- Nov 14, 2019Biorphen® Expected to Launch by End of November
DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 13, 2019
DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 08, 2019Eyes global delivery of Modular Immune Profile (MIP) Assay for Autoimmune Disease
LOS ANGELES, CA – November 8, 2019 – DxTerity Diagnostics Inc. has announced the signing of a multi-year licensing and supply agreement with Thermo Fisher Scientific. Under the terms of the...
- Nov 08, 2019Along with the release of new Longitudinal SLE Clinical Study Results, the diagnostics company announces the commercial launch of DxTerity Type 1 Interferon Testing
LOS ANGELES, CA – November 8, 2019 – DxTerity® Diagnostics Inc. has announced the results of a longitudinal clinical study with the Oklahoma Medical Research Foundation (OMRF) demonstrating...
- Nov 08, 2019—Despite Differing Study Designs, Patient Criteria and Geographies of the Two Landmark Clinical Trials, Results Were Consistent for AR101-Treated Patients Compared to Placebo—
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 08, 2019
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed...
- Nov 08, 2019—New Data at ACAAI Reinforce the Need for Treatments to Reduce the Fear of Accidental Exposure to Peanut and Improve Emotional Well-Being for Adult Patients and Caregivers—
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 08, 2019— Findings Suggest that a Strong Clinical History, in Combination with Evidence of Peanut Sensitization, is the Optimal Approach to Identify Highly Sensitive Peanut-Allergic Patients —
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 07, 2019
FARMINGDALE, N.Y., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
- Nov 06, 2019
DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 06, 2019--Webcast and conference call today at 4:30 p.m. ET--
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 6, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Nov 06, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB :ASPCF) will announce its third quarter 2019 financial and operating results on Thursday, November 14, 2019 before the...
- Nov 06, 2019Third Quarter Net Revenue of $8.6 Million
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $8.6 million for the third quarter ended September 30, 2019. Third Quarter and Recent Operating and...
- Nov 04, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 04, 2019
FARMINGDALE, N.Y., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
- Nov 01, 2019Current NATESTO® supply to the United States remains unaffected
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO® in Canada and South Korea, following the...
- Oct 31, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 31, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Oct 31, 2019Recent Equity Raise and Line of Credit Provides Working Capital and Strengthened Balance Sheet to Fund Growth and Profitability
BIOLASE, Inc. (Nasdaq: BIOL), the global leader in dental lasers, today announced that it has secured a $3 million revolving line of credit from Pacific Mercantile Bank ("the Bank"), the wholly...
- Oct 30, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 30, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Oct 29, 2019
DxTerity Diagnostics has launched the IFN-1 Test for determining a systemic lupus erythematosus patient's type 1 interferon status and the risk of progressing to lupus nephritis. The firm launched...
- Oct 28, 2019
FARMINGDALE, N.Y., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Oct 24, 2019
BIOLASE, Inc. (Nasdaq: BIOL), the global leader in dental lasers, today announced the pricing of an underwritten public offering of 7,820,000 shares of its common stock at a price to the public of...
- Oct 23, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the...
- Oct 23, 2019More Than 250 Dental Professionals Attended The Event To Learn The Latest Trends And Innovations In Dentistry From Leading Industry Experts
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, hosted the inaugural Advancing Dentistry Symposium in San Diego, California Oct. 18-19. More than 250 professionals in the dental...